Kairos Pharma, Ltd. (KAPA) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

• Price: $0.61
• Market Cap: $13.04M
• EPS: $-0.31
• 52-Week High: $2.11
• 52-Week Low: $0.40

Market Sentiment

Kairos Pharma, Ltd. currently has a Bullish sentiment score of 0.44.

About Kairos Pharma, Ltd.

Kairos Pharma, Ltd. (KAPA) is a clinical-stage biopharmaceutical firm headquartered in Los Angeles, California, that is focused on developing innovative therapeutic solutions for cancer. The company boasts a diversified pipeline of proprietary drug candidates targeting significant unmet medical needs within oncology, demonstrating its commitment to enhancing patient outcomes. With its strong emphasis on research and development, Kairos is well-positioned to navigate the competitive biopharmac...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Kairos Pharma, Ltd. and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does KAPA pay dividends?

Kairos Pharma, Ltd. (KAPA) does not currently pay a regular dividend.

What is KAPA's market cap?

Kairos Pharma, Ltd. (KAPA) has a market capitalization of $13.04M with a current stock price of $0.61.